About

Valiant Laboratories operates in pharmaceuticals and biotechnology within the healthcare sector. The company has a market capitalization of ₹469.86 crore and showed significant profitability recovery, with consolidated net profit of ₹21.1 crore in Q1 FY2026-27 following a loss-making prior quarter.

Face value: ₹10

Market cap

₹679 Cr

P/E

42.4×

P/B

2.2×

Dividend yield

0%

ROE

-1.2%

ROCE

0.8%

Debt / equity

0.14

OPM

2.7%

EPS (TTM)

₹2.9

Book value

₹57.2

52-week high

₹127.9

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Operating margin volatility: OPM swung from -1.7% (Dec 2025) to 25.39% (Jun 2026), signaling earnings instability or substantial one-time items
Negative return on equity of -1.2% indicates the company is currently destroying shareholder value
Material divergence between standalone and consolidated results (e.g., Dec 2025: -1.7% vs +0.46% OPM) raises questions about subsidiary performance and consolidation complexity
Thin overall operating margin of 2.69% provides limited cushion for cost shocks or regulatory pricing pressure — verify what drove the Dec 2025 loss and sustainability of recent recovery

Generated analysis · source review pending

Growth drivers

Consolidated revenue jumped 2.5x from ₹46.2 Cr (Sep 2025) to ₹115.29 Cr (Jun 2026); verify if growth reflects organic demand, acquisition consolidation, or one-time orders
Consolidated net profit recovered ₹21.1 Cr (Jun 2026) from ₹-7.06 Cr loss (Dec 2025); clarify operational drivers and validate if turnaround is sustainable
Operating margin of 25.39% (Jun 2026 consolidated) after margins near zero or negative; verify if improvement reflects cost discipline, pricing, or one-time items
EPS recovered to ₹3.89 (Jun 2026 consolidated) from ₹-1.3 (Dec 2025); validate if this profit level recurs

Generated analysis · source review pending

₹125.1+51.5%1Y

Beta

0.47

Damps index moves

Volatility (1y)

50.9%

Annualised, daily returns

RSI (14)

50.3

Neither overbought nor oversold

Rel. strength (1y)

37.8%

Ahead of the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+High promoter holding of 74.9% with no pledge
+Outperformed the universe by 37.8% over 1 year

Cons

−Low return on equity of -0.6% (3-yr avg)
−Thin operating margin of 2.7%
−Revenue shrank over the last 3 years (-10.7% a year)
−Weak interest coverage of 1.4×

Research score

Structured signal from quality, growth, valuation and momentum.

57/100

Business quality: 19
Growth: 67
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	334	182	133	237
COGS	277	168	117	197
Gross profit	57	14	17	40
	23	22	21	34
	34	-8	-5	6
OPM %	10%	-4.6%	-3.5%	2.7%
Depreciation	—	2	2	6
Interest	0	0	0	2
	5	10	5	2
Profit before tax	38	-1	-2	1
Tax	9	-1	1	4
Tax %	24%	-141.6%	45.7%	524.7%
	29	0	-2	-3
PAT margin %	8.7%	0.2%	-1.7%	-1.4%
EPS (₹)	8.9	0.1	-0.5	-0.5
EPS adjusted (₹)	8.9	0.1	-0.5	-0.6
Annual report	—	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	33	43	43	54
Reserves	68	193	191	257
Minority interest	—	—	—	0
	59	76	121	45
	53	30	45	108
Total equity & liabilities	213	343	401	464
	47	50	48	227
CWIP	1	43	156	6
Investments	34	38	0	26
	131	212	197	205
Total assets	213	343	401	464

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	56	2	1	-10
	-55	-144	-53	7
	-1	152	45	2
Net cash flow	-0	10	-7	-1
Free cash flow	18	-44	-113	-45
CFO / Operating profit %	167.2%	—	—	-163.2%

Compounded sales growth

7 years: —
5 years: —
3 years: -11%
1 year: 78%

Stock price CAGR

10 years: —
5 years: —
3 years: —
1 year: 47%

Return on equity

7 years: —
5 years: —
3 years: -1%
Last year: -1%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	16.9%	7.6%	12.6%	17%
EBITDA margin %	10%	-4.6%	-3.5%	2.7%
EBIT margin %	10%	-5.7%	-5.1%	0.1%
PAT margin %	8.7%	0.2%	-1.7%	-1.4%
Working capital
Receivable days	97	92	197	144
Inventory days	17	22	12	84
Payable days	0	56	127	174
NWC days	114	57	82	54
Leverage
Current ratio	2.97	7.76	3.23	1.91
Debt to EBITDA	1.77	—	—	7.03
Debt to equity	0.59	0.32	0.52	0.14
Interest coverage	153.5	-8.6	-7.4	1.4
Asset turnover	1.57	0.53	0.33	0.51
Return ratios
Return on assets %	13.6%	0.1%	-0.5%	-0.7%
Return on capital employed %	23.7%	-0.3%	-0.4%	0.8%
Return on equity %	28.9%	0.1%	-0.9%	-1.1%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	74.94%	74.94%	74.94%	74.94%	74.94%	74.94%	74.94%	74.94%	74.94%	74.94%	74.94%	74.94%
	8.64%	7.08%	3.48%	1.89%	0%	0%	0.64%	0.63%	0.02%	0.01%	0.2%	0%
DII	3.89%	0.47%	0.03%	0%	0%	0%	0%	0.46%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	12.53%	17.51%	21.55%	23.17%	25.06%	25.06%	24.42%	23.97%	25.04%	25.05%	24.86%	25.06%
No. of shareholders	—	—	—	—	—	—	—	—	15,075	14,910	14,657	14,341

Promoter holding up 0 percentage points since Sep 2023.

18 deals · 6 Oct 2023 – 17 Dec 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
17 Dec 2025	METASONI ALLOYS PVT LTD	Bulk	NSE	Buy	3,11,999	₹67.33	₹2.10 Cr
17 Dec 2025	METASONI ALLOYS PVT LTD	Bulk	NSE	Sell	7,742	₹66.98	₹0.05 Cr
13 Jun 2025	TRADE CORNER	Bulk	NSE	Sell	2,35,200	₹120.29	₹2.83 Cr
31 Jan 2025	MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITED	Bulk	NSE	Sell	2,75,000	₹102.75	₹2.83 Cr
31 Jan 2025	NECTA BLOOM VCC - NECTA BLOOM ONE	Bulk	NSE	Buy	2,75,000	₹102.75	₹2.83 Cr
24 Jan 2025	MONEY LOGIX SECURITIES PVT LTD	Bulk	NSE	Buy	5,50,000	₹105.78	₹5.82 Cr
24 Jan 2025	JAINAM BROKING LIMITED	Bulk	NSE	Sell	5,50,000	₹105.77	₹5.82 Cr
7 Jun 2024	JALIYAN COMMODITY	Bulk	NSE	Buy	3,49,143	₹142.81	₹4.99 Cr
7 Jun 2024	JAINAM BROKING LIMITED	Bulk	NSE	Sell	3,44,380	₹142.80	₹4.92 Cr
7 Jun 2024	JAINAM BROKING LIMITED	Bulk	NSE	Buy	12,300	₹148.54	₹0.18 Cr

1–10 of 18

1 / 2

Mr. Mulesh Manilal SavlaNon-Executive - Independent Director-Chairperson
Mr. Paresh Shashikant ShahExecutive Director
Mr. Santosh Shantilal VoraExecutive Director-MD
Mr. Shantilal Shivji VoraNon-Executive - Non Independent Director
Mrs. Sonal Amit ViraNon-Executive - Independent Director
Mr. Sandeep GuptaNon-Executive - Non Independent Director
Mr. Ashok Lakhamshi CheddaNon-Executive - Independent Director
Mr. Akshay GangurdeCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Valiant Laboratories Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

2

Credit ratings

1

Credit Rating issued by India Ratings & Research Private Limited3 Sept 2026 from India Ratings

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results10 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

35 announcementsExport CSV

29 Sept 2026, 5:54 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

29 Sept 2026, 5:46 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

29 Sept 2026, 5:45 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

28 Sept 2026, 5:52 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

17 Sept 2026, 12:17 pmOthers

Board Meeting Outcome for Investment In AMPYR Renewable Energy Resources Twelve A Private Limited

Outcome without intimation PDF

17 Sept 2026, 12:13 pmCompany Update

Announcement under Regulation 30 (LODR)-Acquisition

Acquisition PDF

4 Sept 2026, 12:25 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

3 Sept 2026, 5:40 pmCompany Update

Announcement under Regulation 30 (LODR)-Credit Rating

Credit Rating PDF

Date	Category	Subject	Filing
29 Sept 2026, 5:54 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
29 Sept 2026, 5:46 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF

Loading announcements…

Valiant Laboratories Limited

Valiant Laboratories Limited

About

Key insights

Key risks

Growth drivers

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Stock price CAGR

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Credit ratings

Events

Board meetings1

Announcements

Announcements

Annual reports

Credit ratings

Board meetings1

Ratio timeline

Not in the F&O segment

No fund holdings on record

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Stock price CAGR

Return on equity

1

1